SpringWorks Therapeutics

SWTX · NASDAQ

Price unavailable right now.

No price history for this range.

SWTX analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Jul 3, 2025

Bull case

SpringWorks Therapeutics Inc. is strategically positioned to capitalize on its recent product approvals, OGSIVEO and GOMEKLI, which are expected to drive significant market interest and create potential acquisition opportunities within the biopharmaceutical sector. With approximately $461.9 million in cash and cash equivalents as of the end of 2024, the company is well-funded to support its operations until projected profitability in 2026. The competitive clinical profiles of its products, particularly GOMEKLI's broader market access compared to existing treatments, enhance its outlook for outperforming initial estimates, underscoring SpringWorks's attractiveness as a promising oncology enterprise.

Bear case

SpringWorks Therapeutics is projected to incur a full-year net loss of $2.65 million in 2025, indicating potential financial strain. The company faces substantial risks related to the commercialization and market expansion of its key products, nirogacestat and mirdametinib, as well as the possibility of clinical setbacks with other candidates like brimarafenib. Additionally, the threat of long-term dilution poses a further risk to investors, particularly in light of the dependence on achieving regulatory and clinical success for its developmental programs.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.